![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer |
Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang |
Cancer Research and Treatment. 2014;46(3):234-242. Published online 2014 July 15 DOI: https://doi.org/10.4143/crt.2014.46.3.234 |
A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer 359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies A phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results 1472 POSTER A phase I study with fosfluridine tidoxil, a novel oral fluoropyrimidine, in patients with advanced solid tumors First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours 1454 POSTER A phase I dose-finding study of pemetrexed combined with paclitaxel in patients with advanced solid tumors 1459 POSTER A phase I clinical study of weekly heptaplatin and paclitaxel in previously treated patients with advanced solid tumor 1209 POSTER ONX 0912, a Novel Oral Proteasome Inhibitor (PI), in Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study 36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours |
This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014. |